- Citations, last 5 years
- 309
- Works, last 5 years
- 25
- h-index
- 66
- Scientists listed
- 2
- Grants since 2016
- 13
Grants received
2021–2025 · research · R01
Vamorolone trial in Becker muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by U.S. Food and Drug Administration
2021–2024 · research · R01
Vamorolone trial in Becker muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by U.S. Food and Drug Administration
2019–2020 · research · R44
Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials
Paula R Clemens · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials
Eric P. Hoffman · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2018–2021 · research · R41
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
Jesse Damsker · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis
Jesse Damsker · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2022 · grant · SB1
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales
Eric P. Hoffman · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2020 · research · R44
Pivotal trial of vamorolone in Duchenne muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2020 · research · R44
Pivotal trial of vamorolone in Duchenne muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2022 · grant · SB1
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales
Eric P. Hoffman · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Phase IIa study of VBP15 for Duchenne muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Phase IIa study of VBP15 for Duchenne muscular dystrophy
Paula R Clemens · ReveraGen BioPharma (United States) · funded by National Institutes of Health
2016–2018 · research · R41
Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis
Jesse Damsker · ReveraGen BioPharma (United States) · funded by National Institutes of Health